Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the million women study
| Autor: | B Crossley, Elizabeth Kutt, Gillian K Reeves, Peter Briers, Elizabeth Hilton, Janet Lavelle, Diana Bull, Stephen Bailey, Ruth English, Linda Rockall, Julietta Patnick, Alan Jackson, Mary E. Wilson, Moya Simmonds, Emily Banks, MG Wallis, Valerie Beral, Nigel Barrett |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
Million Women Study
medicine.medical_specialty Pediatrics Hormone Replacement Therapy Breast Neoplasms Breast cancer Risk Factors medicine Mammography Humans Mass Screening False Positive Reactions Referral and Consultation Mass screening General Environmental Science Gynecology medicine.diagnostic_test business.industry General Engineering General Medicine Middle Aged medicine.disease United Kingdom Menopause Transgender hormone therapy Relative risk Papers General Earth and Planetary Sciences Regression Analysis Female business Body mass index |
| Popis: | About half of the women attending the NHS breast screening programme have used hormone replacement therapy.1 Although previous studies have reported that use of hormone replacement therapy increases the risk of being recalled after mammography for further assessment, with no subsequent diagnosis of breast cancer (“false positive recall”), the effect of different patterns of use is unclear.2 Relative risk of false positive recall in postmenopausal women in relation to time since last use of hormone replacement therapy. (Relative risk compared with never users (1057/44 427 recalled) stratified by screening centre, age, previous screening, body mass index, previous breast operation, and time since menopause in: current users of hormone replacement therapy (relative risk 1.64, 95% confidence interval 1.50 to 1.80; 1157/28 634 recalled); past users ceasing use |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|